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Stroke risk stratification in atrial fibrillation: a review of common risk factors
Oreoluwa Oladirana and Ifeanyi Nwosub
aDepartment of Internal Medicine, Reading Hospital, Tower health system, West Reading, PA, USA; bDepartment of Internal Medicine,
Leighton Hospital NHS Trust, Crewe, Cheshire, UK
ABSTRACT
Atrial Fibrillation (AF) has become a major global health concern being the most common
sustained arrhythmia in clinical practice. Risk factors for AF include congestive heart failure,
hypertension, increasing age and diabetes. Many of these factors also increase the risk for
thromboembolism and ischemic stroke in AF patients. Great efforts have been made from the
latter part of the 20th century towards developing an ideal stroke risk stratification tool in AF
with the aim of reducing the incidence of stroke in AF patients and the limiting unnecessary
use of thromboprophylaxis. The thromboembolic risks posed by AF with valvular heart
disease are an important subgroup that contributes to a significant proportion of stroke in
AF patients globally. We review the evolution of stroke risk stratification and summarize the
guidelines for stroke prevention in non-valvular AF as well as AF with valvular heart disease,
and the most recent recommendations on stroke prevention in AF patients.
Abbreviations: AF: Atrial Fibrillation; ACS: Acute Coronary Syndrome; CAD: Coronary Artery
Disease; CCF: Congestive Cardiac Failure; DM: Diabetes Mellitus; EHRA: Evaluated Heartvalves,
Rheumatic or Artificial; ICH: Intracranial Hemorrhage; NOACs: Novel Oral Anticoagulants; OAC:
Oral Anticoagulants; PAD: Peripheral Arterial Disease ; TIA: Transient Ischemic Attack; VHD:
Valvular Heart Disease.
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1. Introduction
Atrial fibrillation (AF) is a supraventricular tachyarrhyth-
mia characterized by uncoordinated atrial activationwith
consequent deterioration of atrial mechanical function
[1]. As one of themost studied cardiovascular diseases, its
understanding has evolved through decades. Currently
affecting about 2.7–6.1million people in the USA [1] and
33 million people worldwide [2], with an annual risk of
ischemic stroke estimated to be about 5–7%[3], the cor-
nerstone of management remains interventions for rate
control, rhythm control and thromboprophylaxis. More
recently, the focus has been to streamline patientmanage-
ment pathways, to approachAFmanagement in a holistic
or integrated manner, as follows (the ABC or Atrial
fibrillation Better Care Pathway- Figure 1): ‘A’ Avoid
stroke with Anticoagulation; ‘B’ Better symptom care,
with patient-centred symptom directed decisions on
rate or rhythm control; and ‘C’ Cardiovascular and
comorbidity risk management, including attention to
risk factors and lifestyle changes [4]. The ABC approach
has shown that compliance with such optimised care is
associated with a significant reduction in mortality and
hospitalisations [5], and a reduction in healthcare cost
associated with cardiovascular events [6]. This review
aims to provide a historic perspective on the evolution
of stroke risk classifications in AF with particular
emphasis on the most widely used system – the CHA2
DS2VASc score, its individual components and their
contribution to the overall risk of stroke.
2. Individual risk factors for stroke in atrial
fibrillation
Among many other factors that increase the risk of
stroke, AF is an independent risk factor for ischemic
stroke and studies showed that this risk is increased by
a factor of five in patients with AF [7,8]. AF is associated
with major systemic thromboembolism and about
a third of patients with ischemic stroke have been
found to have either clinical or subclinical AF [9] due
to high prevalence of left atrial thrombosis [10]. Since
oral anticoagulation (OAC) is known to reduce the
incidence of stroke in AF, timely diagnosis and use of
anticoagulant is imperative for stroke prevention [11].
Over the years several stroke risk stratification systems
have been developed using common and validated stroke
risk factors in patients with AF, to aid decision-making
for thromboprophylaxis. Most of these systems utilise
acronyms to represent various individual risk factors
and are scored accordingly. Although stroke risk is
a continuum, patients have been artificially classified as
low, intermediate and high risk for stroke and decision to
commence thromboprophylaxis are made to avoid
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unnecessary use of OAC [12]. A major shift in the stroke
risk stratification is the identification of low risk group to
minimize needless anticoagulation.
One of the earliest stroke risk stratification systemwas
the Framingham score [13], a points-based system
assessed various clinical factors and assigned scores as
follows: Age (0–10), female sex (6), systolic hypertension
(0–4), diabetes mellitus (5), and prior stroke or transient
ischemic attack (TIA) (6). Scores >8 were considered
increased risk and required thromboprophylaxis [14].
TheAtrial Fibrillation Investigators (AFI) sought to iden-
tify patient features predictive of stroke risk and found
that patients withAF less than 65 years without hyperten-
sion, previous stroke or transient ischemic attack or
diabetes were at very low risk for stroke and were not
anticoagulated [15,16]. The stroke prevention in atrial
fibrillation (SPAF) trial also identified recent congestive
heart failure (within 3 months), history of hypertension
(systolic blood pressure >160mmHg) and previous arter-
ial thromboembolism as independent risk factors for
thromboembolism in atrial fibrillation [17]. In 2001,
Gage et al devised the CHADS2 score by merging the
AFI and SPAF classification schemes, testing this in
a cohort of hospitalised AF admissions [18]. The
CHADS2 score assesses the individual risk factors and
scores 1 point for congestive cardiac failure, hyperten-
sion, age 75 years and above and diabetes mellitus. Prior
stroke or transient ischemic attack is assigned 2
points [18].
In 2010, a revised clinical risk stratification tool for
predicting stroke and thromboembolism in AF [19] pro-
vided some improvement in the predictive value of the
existing CHADS2 schema by including age 65–74 years,
vascular disease and female gender to form the CHA2
DS2VASc score (Table 1). This is currently a widely used
scoring system in guidelines for stroke in AF as it usefully
identifies low risk patients with AF. Piccini et al in 2012
noted that renal dysfunction was an independent risk
factor for stroke in patients with AF and thus the R2
CHADS2 scoring system was introduced with 2 points
assigned to creatinine clearance less than 60ml/min [20].
This is perhaps unsurprising as renal impairment often
coexists with components of the CHADS2 and CHA2DS2
-VASc scores. Latter studies disputed the relevance of
renal impairment as an independent risk factor for stroke
in AF as it failed to improve the predictive ability of
CHADS2 and CHA2DS2-VASc score [21]. Despite the
use of the various risk stratification systems, a significant
number of strokes are still noted in patients with AF
classified as low risk and not requiring thromboprophy-
laxis. The need to further identify other risk factors for
thromboembolic event led to the introduction of the
ATRIA (anticoagulant and risk factors in atrial fibrilla-
tion) score [22] which in addition to existing risk factors,
also included age categories, presence of proteinuria and
estimated glomerular filtration rate less than 45 or end
stage renal disease. While a study by Van Den Ham et al
noted that the ATRIA score better identified low risk
patients for stroke than the CHA2DS2-VASc score [23],
various other cohort studies concluded that CHA2DS2-
VASc score had better correlation with thromboembo-
lism in non-anticoagulated patients with AF than the
newer R2CHA2DS, ABC-stroke score and ATRIA scor-
ing systems [24,25] The Canadian Cardiovascular
Society adopted the CHADS65 risk score, which incor-
porated the CHADS2 and CHA2DS2-VASc risk factors
proposing a guideline for thromboprophylaxis in
patients with AF. This risk score considered age
65 years and above as a cut-off and recommend the use
of OAC in AF patients with CHADS2 ≥ 1 and age ≥
65 years. Aspirin was recommended for patients with
stable coronary artery disease (CAD)/peripheral vascular
disease (PVD), or those age< 65 years, and no
Figure 1. Illustrating the atrial fibrillation better care pathway for integrated management of patients with atrial fibrillation [4].
Table 1. Individual components of the CHA2DS2-VASc risk
factors [19]. CHA2DS2-VASc score.
Risk Factors Scores
Congestive heart failure/Left ventricular dysfunction 1
Hypertension 1
Age ≥75Yrs 2
Diabetes mellitus 1
Stroke/TIA 2
Vascular disease (prior myocardial infarction, peripheral artery
disease
1
Age 65 to 74 years 1
Sex category (female) 1
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thromboprophylaxis in patients < 65 with CHADS2 of 0,
in the absence of CAD/PVD [26]. In 2013, Hippisley-
Cox et al developed and published the Qstroke algo-
rithm, which is an electronic model that calculates the
risk of stroke or TIA without prior stroke or TIA based
on several risk factors such as age, ethnicity, sex, smoking
status, clinical diagnosis of diabetes, treated hyperten-
sion, kidney disease, rheumatoid arthritis, angina, cor-
onary heart disease, congestive cardiac failure, valvular
heart disease, and clinical values including ratio of total
serum cholesterol to high density lipoprotein cholesterol
concentrations, bodymass index as well as family history
of coronary heart disease in first degree relative under
60 years. Its performance was compared to the existing
scoring systems mainly the CHADS2 and CHA2DS2
VASc scores. Qstroke was found to improve the perfor-
mance of both CHADS2 and CHA2DS2VASc in asses-
sing high risk patients who might benefit from
anticoagulation [27]. The quest to find an ideal stroke
risk stratification tool continued as a significant popula-
tion of non-anticoagulated low risk patient was seen to
have thromboembolic events. The Global Anticoagulant
Registry in the FIELD–Atrial Fibrillation (GARFIELD
study) [28] used a computer-generated risk model that
predicted all-cause mortality, ischaemic stroke/systemic
embolism (SE) and haemorrhagic stroke/major bleeding
in low-risk atrial fibrillation (AF) patients – and pro-
posed the GARFIELD-AF score which was superior to
CHA2DS2-VASc in predicting risk of ischemic stroke in
AF patients with low risk of stroke [29]. In the Southern
hemisphere, the National Heart Foundation of Australia
(NHF) and the Cardiac Society of Australia and New
Zealand (CSANZ) published a national guideline for
stroke prevention in patients with AF. They recom-
mended the use of the ‘sexless CHA2DS2-VASc score’
ie. the CHA2DS2-VA risk score, and preference was
given to non-vitamin K antagonist oral anticoagulants
(NOACs) over vitamin K antagonists (VKA) in patients
with scores ≥ 1 [30].
Currently, given its relative simplicity the CHA2DS2-
VASc score is still the most widely used scoring system
and the 2018 American College of Chest Physicians
(ACCP) CHEST guidelines recommend the use of oral
anticoagulants, preferably NOACs for patients with
a single non-sex CHA2DS2-VASc risk factor (score of
≥ 1 in males, ≥ 2 in females) rather than no anticoagula-
tion or use of single or dual anti-platelet therapy [31].
2.1. AF patients with valvular heart disease
Much emphasis has been placed on the risk of throm-
boembolism in patients with non-valvular AF.
Nevertheless, there remains a significant risk of throm-
boembolism in AF with valvular heart disease (VHD).
This category refers to AF in patients with rheumatic
mitral valve stenosis or mechanical prosthetic valve
[32]. Unlike in non-valvular AF where left atrial
thrombus is mostly formed, patients with AF with
VHD are at much higher risk of thromboembolism and
the formation of the thrombus occurs mostly outside the
left atrium for unclear reasons. This risk is not only
related to the degree of valvular disease, but it is also
affected by various CHA2DS2-VASc risk factors [32].
Over the years, there has been confusion regarding the
type of anticoagulation therapy to be used in patientswith
non-valvular AF and patients with AFwith valvular heart
disease with respect to VKA vs NOACs.
With the need to address this, the European Heart
Rhythm Association (EHRA) published a consensus
document which proposed categorizing patients with
AF into 2 groups based on the type of OAC used for
thromboprophylaxis thus the EHRA (Evaluated
HeartValves, Rheumatic or Artificial) [32]. EHRA Type
1 patients are those with AF and VHD requiring therapy
withVKA. TheVHDconsidered in this category are only
mechanical prosthetic valves or rheumaticmitral stenosis
with moderate-severe dysfunction. The options of
NOACs versus VKA for anticoagulation in patients
with valvular AF was explored by the RE-ALIGN trial
which compared Dabigatran an oral direct thrombin
inhibitor against Warfarin in AF patients with mechan-
ical valve [33]. The study concluded that Dabigatran was
less effective compared to Warfarin and associated with
increased risk of bleeding and thromboembolic event
[34]. Contrary to this finding, a prospective DAWA-
study reported that NOACs are as effective as VKA in
valvular AF [34]. However, the study had several short-
comings notably the small sample size and premature
termination of the study due to poor enrolment. Further
studies are needed to determine the benefits of NOACs
over Warfarin for patients with valvular AF.
EHRA Type 2 patients are those with AF and VHD
requiring therapy with either VKA or NOACs based on
CHA2DS2-VASc risk levels. The VHD considered in this
category includes mitral regurgitation, mitral valvular
repair, aortic stenosis and regurgitation, bioprosthetic
valves, pulmonary valve stenosis and regurgitation, tri-
cuspid valve stenosis and regurgitation, and a trans-aortic
valve intervention. However, it is important to note that
while patients with bioprosthetic valves were excluded
from the NOAC trials namely ROCKET-AF [35], RE-LY
[36] andARISTOTLE [37], their use is considered accep-
table. Although bioprosthetic valves are known to be less
thrombogenic, further research is required to determine
long term safety of NOACs in patients with bioprosthetic
valves requiring anticoagulation.
3. Congestive heart failure
Congestive heart failure (CHF) which represents the ‘C’
in the CHA2DS2VASc scoring system, is considered
a cause and effect of AF and is associated with increased
morbidity and mortality [38]. In older scoring systems
such as CHADS2, heart failure only referred to recent
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decompensated heart failure and there was some uncer-
tainty as to whether or not heart failure with preserved
ejection fraction (HFpEF; left ventricular ejection frac-
tion >50%) or heart failure with reduced ejection frac-
tion (HFrEF; left ventricular ejection fraction <40%) or
asymptomatic systolic or diastolic dysfunction was
being included.
Banerjee et al sought to establish the role of ejection
fraction in risk prediction in patients with non-valvular
AF and heart failure. They found no difference in rates of
stroke, systemic thromboembolism or death between the
different heart failure categories [39]. Sandhu et al also
assessed this relationship among participants of ACTIVE
(Atrial Fibrillation Clopidogrel Trial with Irbesartan for
Prevention of Vascular Events) trial in which, among
patients with heart failure, neither the presence of left
ventricular systolic dysfunction nor the degree of symp-
tom severity influenced the risk for embolic events [40].
Therefore, the decision about risks and benefits of antic-
oagulation for heart failure patients with AF should not
be influenced by ejection fraction or symptom status.
4. Hypertension
Hypertension is the most prevalent risk factor for new-
onset atrial fibrillation. Controlled or uncontrolled
hypertension and history of hypertension scores a point
in the CHA2DS2VASc score. In one study, the observed
absolute stroke risk from hypertension alone as a risk
factor in non-anticoagulated patients with atrial fibrilla-
tion was about 1.5–3.0% per year [41].
A cross-sectional longitudinal analysis using data
from Stroke prevention using an Oral Thrombin
inhibitor in atrial Fibrillation (SPORTIFF) III and
V trials showed an increase in stroke rate with
increasing systolic blood pressure in patients with
AF. Hypertension contributes to increased stroke
with events rates increased at systolic blood pressure
(SBP) levels of 140 mmHg and above. However,
controlled hypertension with mean SBP
<140 mmHg, is associated with a lower risk of stroke
compared with patients with poorly controlled hyper-
tension. Notably, in the aspirin arm of SPAF III trial,
even subjects with a history of hypertension had an
increased risk of stroke in AF [42].
5. Age
The Framingham study and more recent studies estab-
lished age as a significant and independent risk factor
for AF associated stroke [7,43–45]. Studies also showed
that in patients with lone AF (without other risk fac-
tors), the risk of stroke significantly increased in
patients >60 years [46]. Studies have also shown that
the highest risk of stroke in AF was found in patients
aged 75 years and above. For this reason, the CHA2DS2-
VASc score assigned a score of 2 for age ≥ 75 years and 1
for ages 65–74 years. In Asia, the age threshold may
even be lower, with ischemic stroke rates approximately
1.5%/year in patients 50–64 years [47] leading to a sug-
gestion of a modified CHA2DS2VASc score for Asians,
with 1 point given for age 50–74 years.
Physicians are often reluctant to use OAC in elderly
patients due to the potential life-threatening complica-
tions associated with its use. Studies have shown that the
benefits of OAC also increases with advancing age as
stroke is known to increase with age. A large cohort study
in Asia demonstrated that among patients >90 years,
warfarin use was associated with a lower risk of ischemic
stroke (HR, 0.69 [0.49–0.96]) and a positive net clinical
benefit [47]. NOACs were associated with lower risk of
ICH (HR, 0.32 [0.10–0.97]) without difference in
ischemic stroke risk compared to warfarin.
Although age is a component of several bleeding risk
scores, it should not be used solely to negate the use of
OACs in elderly patients [45]. Anticoagulation in
elderly often requires benefit-risk conversation with
patients and relatives. It is also important not to over-
emphasize the bleeding risk associated with elderly falls
as studies have shown that the absolute risk of bleed in
those on anticoagulants is small [48].
6. Diabetes mellitus
Diabetes mellitus (DM) is known to increase both the
risk of AF and development of stroke in AF [49–51].
Arrhythmogenicity may be associated with the acceler-
ated atherosclerosis in diabetes with structural, electrical
and autonomic remodelling [52]. DM independently
increases the risk of stroke in patients with AF by 1.7
fold with other studies noting an absolute stroke rate of
2.0–3.5% per year in the absence of other risk factors in
non-anticoagulated AF patient [46].
Among participants of the ATRIA (Anticoagulation
and Risk Factors in Atrial Fibrillation) study, duration
of diabetes (>3 years) was strongly associated with
increased risk of stroke compared to having diabetes
for less than 3 years (HR: 1.74, 95% CI 1.10–2.76). They
also found that neither poor glycemic control (HA1c >
9.0%, HR 1.04, 95% CI: 0.57–1.92) nor moderately
increased HA1c (7.0–8.9%, adjusted HR: 1.21, 95% CI:
0.77–1.91) were significantly associated with an
increased rate of ischemic stroke compared with
patients who had HA1c <7.0%. Therefore, duration of
diabetes is a more important predictor of ischemic
stroke than glycemic control in diabetic patients with
AF [53].
A study by Fangel et al using data from Danish
nationwide registry also found that among patients
<65 years, there was higher risk of thromboembo-
lism among those with type 2 diabetes compared to
those with type 1 diabetes. However, overall no
independent association was found between type
of diabetes (type 1 versus type 2) and the risk of
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thromboembolism in non-anticoagulated patients
with AF [54].
7. Stroke/transient ischemic attack
Previous stroke or transient ischemic attack (TIA) is
perhaps the strongest independent risk factor for stroke
in patients with AF. Studies have shown that this risk is
increased by 2.5-fold following a previous stroke of TIA
[55]. Interestingly, a significant association was found
between prior intracranial hemorrhage (ICH) and
ischemic stroke in patients with AF in a study by
Friberg et al. whereby AF patients with prior ICH are
at increased risk of having an ischemic stroke [56].
8. Vascular disease
This component is unique to the CHA2DS2-VASc
scoring system and not present in other stroke risk
scores. This refers to atherosclerotic vascular diseases
such as prior myocardial infarction, complex aortic
plaques (>4mm thick or presence of mobile debris
[57]) and peripheral arterial disease [58]. Peripheral
arterial disease (PAD) is also observed to increase the
risk of incident AF in elderly patients with risk
increasing with progressively lower ankle-brachial
pressure index (ABPI).
Recent evidence showed that vascular diseases
including acute coronary syndrome (ACS) and per-
ipheral artery disease (PAD) are a predictor of AF
related stroke and thromboembolism and improves
the predictive ability of CHADS2 score [59]. Studies
showed that peripheral artery disease alone increases
the risk of stroke with poor outcome in patients with
AF whereas an uncomplicated ACS is less a risk
factor than myocardial infarction and angina pectoris
[60]. In patients with atrial fibrillation and vascular
disease with no additional non-sex risk factors, the
risk of ischemic stroke was increased by 1.68 in males
and 2.15 in females [61].
In a large cohort study using the Danish National
Patient Registry, coronary artery disease (defined as
obstructive (≥50%) coronary stenosis in ≥1 coronary
vessel or non-obstructive coronary stenosis in ≥2
coronary vessels) conferred a 29% increased risk of
ischemic stroke, TIA or thromboembolism among
patients with AF suggesting that coronary artery dis-
ease (CAD) was an independent risk factor for
ischemic stroke hence the recommendation to
include this component in stroke risk scores among
AF patients [62].
9. Sex category
Even in the absence of atrial fibrillation, women have
higher lifetime risk of stroke than men. The CHA2
DS2-VASc scoring system introduced sex as a factor
for stroke in AF. Various studies showed that female
sex is a strong independent risk factor [63–65]. This
may be related to post-menopausal vascular changes
related to the reduction in estrogen. This affects lipid
metabolism, increases the risk of left ventricular
remodelling and hypertension, and leads to increase
in inflammatory and procoagulant markers all con-
tributing to thromboembolism [64]. In a large cohort
study using data from Atrial Fibrillation Follow-up
Investigation of Rhythm Management (AFFIRM)
trial, hormone replacement therapy (HRT) did not
independently predict mortality, thromboembolism
or bleeding among women with atrial fibrilla-
tion [66].
A score of 1 point is attributed to the female
gender in the CHA2DS2-VASc score. In a cohort
study using the Danish national register involving
87,202 patients with atrial fibrillation, the risk of
stroke and thromboembolism in females less than
74 years was not increased compared to men; how-
ever, females aged ≥ 75 years had increased stroke
rates compared to males in the same group with HR
1.20 (95% CI 1.12–1.28) recommending that female
sex should not be an independent score in the
absence of other risk factors [63].
In a meta-analysis of 17 studies comparing males
and females with atrial fibrillation for the outcome of
stroke and thromboembolism, 10 demonstrated
increased risk of stroke in women revealing 1.31
fold (95% CI 1.18–1.46) elevated risk of stroke in
women with atrial fibrillation, more so in women
aged 75 years or more [67]. The annual stroke rate
for males with only one risk factor and a CHA2DS2-
VASc score of 1 is similar to that of females with 1
additional risk factor and CHA2DS2-VASc a score of
2 (1.96–3.50% versus 1.91–3.34%).
Thus, the female gender should be considered
a risk modifier rather than a risk factor on its own
in the absence of other risk indices in patients with
AF and the decision to start OAC should be guided
by the CHA2DS2-VASc score without the sex cate-
gory component because the sex category risk com-
ponent accentuates the stroke risk in women already
eligible for OAC based on the presence of 2 or more
risk factors [61,68].
10. Non CHA2DS2-VASc risk factors
Apart from the well-established CHA2DS2-VASc risk
factors, other factors may independently contribute to
increased stroke risk in AF patients, one of such is
obstructive sleep apnea (OSA). Several studies noted an
association between OSA and increased risk of ischemic
stroke [69,70]. It remains unclear whether OSA should
be factored independently into the risk stratification as
patients with OSA may have co-existing CHA2DS2-
VASc factors. Kabra et al proposed a modification of the
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CHA2DS2-VASc score to the CHA2DS2-VASc-R score
based on the findings of increased risk of stroke in
African-American patients with AF [71]. However, the
conclusion that race presented an additional risk in
patients with AF was met with scepticism [72,73].
Studies have linked inflammation to the risk of AF and
AF related thromboembolism. Higher levels of pro-
Inflammatory cytokines have been documented in
patients with AF, although it remains unclear whether
the raised levels are directly due to AF or an underlying
cardiovascular disease [74]. Irrespective of this fact,
inflammation confers a prothrombotic state and
increases stroke risk in AF patients [74]. The role of
inflammatory makers in AF management and risk stra-
tification is still undetermined.
11. Conclusion
Atrial fibrillation is amajor risk factor for stroke and the
incidence of stroke remains high in patients with AF
with or without valvular heart disease. As the preva-
lence of AF approaches epidemic proportions, stroke
prevention remains one of the cornerstones of manage-
ment. To minimize the risk of stroke, careful evaluation
of stroke and bleeding risk must be undertaken with
prompt initiation of thromboprophylaxis where neces-
sary. The development of various scoring systems over
the years has simplified the evaluation, with the CHA2
DS2VASc scoring system being the most widely used.
Use of the CHA2DS2VASc scoring system reliably
excludes patients at low risk for thromboembolism.
Current guidelines recommend prompt initiation of
thromboprophylaxis, preferably NOACs for AF
patients with one or more non-sex CHA2DS2VASc
risk factor (≥1 in males, ≥2 in females).
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